With the announcement of the 2024 Nobel Prize in Physiology or Medicine, microRNA has once again become the focus of global attention. In the past 20 years, three Nobel Prizes have been awarded to the field of RNA molecular research, namely “RNA interference mechanism – double-stranded RNA gene silencing (RNAi)” in 2006, “mRNA vaccines based on modified bases” in 2023, and “microRNA in post-transcriptional gene regulation” in 2024. By studying different types of RNA, scientists have subverted people’s previous understanding of the role of RNA in the regulation of gene expression, unveiled the mystery of RNA as the engine of evolution of organisms, and as the control of genetic information flow. This opens a new window for us to understand the basic mechanisms of life sciences, and also opens up new ideas for the diagnosis and treatment of diseases.
The Mrna Mab innovative monoclonal antibody technology platform is launched following this trend, which covers mRNA sequence design, mRNA in vitro transcription and purification, mRNA-LNP packaging, mRNA-LNP animal immunization, STAL phage display antibody library construction, automated antibody library screening, Bac-to-Mammalian full-length antibody production, integrated antibody screening and other technologies, which can provide one-stop innovative antibody research and development from target to high-quality monoclonal antibody.
This platform from Sanyou Bio has a number of advantages: 1) AI-assisted design of the mRNA non-coding region (UTR) sequence to enhance the mRNA stability; 2) Optimization of the mRNA coding region (CDS) sequence based on the sequence analysis software independently developed by the company, which can enhance the mRNA stability and improve the translation efficiency; 3) mRNA animal immunization which can obtain equivalent serum titers, and reduce the preparation cost and time of difficult-to-express antigens. In addition, Sanyou Bio has established a complete mRNA supply chain, which ensures the stability, efficacy and integrity of mRNA from preparation to LNP packaging.
Sanyou Bio’s mRNA platform jumps out of the limitations of protein targets, further expands its one-stop service for antigen preparation and antibody discovery, and develops customized plans according to different target types to meet customers’ needs. For proteins that are difficult to prepare in vitro, such as multi-transmembrane proteins (e.g., CD20) and GPCR proteins (e.g., CCR8), mRNA immunization can not only reduce the cost and time of antigen preparation, but also maintains comparable serum titer compared to conventional VLP and cell line immunization.
